|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Albireo Pharma Inc (ALBO) |
|
|
$44.15 0.00 (0.00%) as of 4:30 Thu 3/2
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,710,000 |
| Market
Cap: |
914.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$44.15 - $44.15 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Albireo Pharma is a commercial-stage biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Co.'s product pipeline includes: Bylvay, which is approved in the U.S. and Europe for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its primary candidate for the treatment of adult liver diseases; and A2342, its primary preclinical candidate for the treatment of adult viral and liver diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
440,064 |
| Total Sell Value |
$0 |
$0 |
$0 |
$10,197,777 |
| Total People Sold |
0 |
0 |
0 |
8 |
| Total Sell Transactions |
0 |
0 |
0 |
39 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reding F Scott |
Chief Financial Officer |
• – – |
2007-05-16 |
4 |
B |
$15.00 |
$49,350 |
I/I |
3,290 |
3,290 |
1.99 |
- |
|
| Reding F Scott |
Chief Financial Officer |
• – – |
2007-05-16 |
4 |
B |
$15.00 |
$21,600 |
D/D |
1,440 |
1,440 |
2.74 |
- |
|
| Weisman Scott |
Director |
– • – |
2007-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
58,156 |
443,136 |
|
- |
|
| Ware R Timmis |
Corp. Secy and General Counsel |
• – – |
2007-05-16 |
4 |
A |
$0.00 |
$0 |
I/I |
22,492 |
110,433 |
|
- |
|
| Vivo Ventures V, Llc |
10% Owner |
– – • |
2007-05-16 |
4 |
A |
$0.00 |
$0 |
I/I |
1,078,933 |
1,685,632 |
|
- |
|
| Great Point Partners I Lp |
10% Owner |
– – • |
2007-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,258,756 |
1,966,574 |
|
- |
|
| Steiner Solomon |
President & CEO |
• • • |
2007-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
94,449 |
147,559 |
|
- |
|
| Weisman Scott |
Director |
– • – |
2007-05-10 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
384,980 |
|
- |
|
| Steiner Ventures Llc |
10% Owner |
– – • |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,136,707 |
|
- |
|
| Vivo Ventures V, Llc |
10% Owner |
– – • |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
606,699 |
|
- |
|
| Cha Albert |
Director |
– • – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
606,699 |
|
- |
|
| Cha Albert |
Director |
– • – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
318 |
|
- |
|
| Kroin David |
Director |
– • – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
707,818 |
|
- |
|
| Kroin David |
Director |
– • – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
318 |
|
- |
|
| Great Point Partners I Lp |
10% Owner |
– – • |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
707,818 |
|
- |
|
| Lorber Daniel |
Director |
– • – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,188 |
|
- |
|
| Pohl Roderike |
Vice President, ResearchOffice |
• – – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
244,168 |
|
- |
|
| Pfutzner Andreas |
Chief Medical OfficerOfficer |
• – – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,272 |
|
- |
|
| Steiner Erik |
Vice President, OperationsOffi |
• – – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
244,168 |
|
- |
|
| Ware R Timmis |
Corp. Secy and General Counsel |
• – – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
17,091 |
|
- |
|
| Ware R Timmis |
Corp. Secy and General Counsel |
• – – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,425 |
|
- |
|
| Feldstein Robert |
Vice PresidentOfficer |
• – – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,647 |
|
- |
|
| Steiner Solomon |
President and CEOOfficer |
• • • |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,136,707 |
|
- |
|
| Steiner Solomon |
President and CEOOfficer |
• • • |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
53,110 |
|
- |
|
| Wertheimer Samuel P |
Director |
– • – |
2007-05-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
708,136 |
|
- |
|
479 Records found
|
|
Page 19 of 20 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
